GALC抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P04893(GALC Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04893(GALC Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

**Background of GALC Antibodies**

Galactocerebrosidase (GALC) is a lysosomal enzyme critical for hydrolyzing galactosylceramide and psychosine, sphingolipids essential for myelin maintenance. Mutations in the *GALC* gene lead to enzyme deficiency, causing toxic psychosine accumulation and progressive demyelination, as seen in Krabbe disease, a fatal neurodegenerative disorder. GALC antibodies are immunological tools designed to detect, quantify, or inhibit GALC protein expression, aiding in research and diagnostics.

These antibodies are pivotal in studying Krabbe disease mechanisms, monitoring GALC expression in cellular or animal models, and evaluating therapeutic approaches like gene therapy or enzyme replacement. Commercially available GALC antibodies (monoclonal or polyclonal) are validated for techniques such as Western blot, immunohistochemistry, and ELISA, often targeting specific epitopes in human, mouse, or rat samples. Challenges in antibody development include ensuring specificity due to GALC's structural homology with other hydrolases and its low abundance in tissues.

In clinical settings, GALC antibodies assist in confirming reduced enzyme levels in patient fibroblasts or leukocytes, supporting newborn screening follow-ups. Recent advances also explore their utility in biomarker discovery and targeted therapies. Overall, GALC antibodies remain indispensable for unraveling lysosomal storage disorders and advancing translational research.